Objective: To investigate the clinical effect of combined treatment with ethinylestradiol and cyproterone acetate tablets and hysteroscopy for perimenopausal AUB. Methods: Using random number table method, 120 perimenopausal patients with AUB admitted to the hospital from July 2023 to January 2025 were divided into the observation group (60 cases treated with hysteroscopy and ethinylestradiol and cyproterone acetate tablets) and control group (60 cases treated with hysteroscopy). The two groups were compared on menstrual blood volume, menstrual cycle, endometrial thickness, hemoglobin, hematocrit, coagulation function, sex hormone levels and the incidence of adverse reactions. Results: Compared with the control group after treatment, the observation group showed reductions in menstrual blood volume, menstrual period, endometrial thickness, APTT, PT, TT, E2, FSH and LH (P<0.05), and rises in hemoglobin and hematocrit (P<0.05). The overall incidences of adverse reactions in the two groups were comparable (P>0.05). Conclusion: For perimenopausal patients with AUB, the combined treatment with ethinylestradiol and cyproterone acetate tablets and hysteroscopy can effectively improve bleeding symptoms, endometrial thickness and coagulation function, and regulate sex hormone levels.
Keywords: Abnormal uterine bleeding; Perimenopause; Ethinylestradiol and cyproterone acetate tablets; Hysteroscopy